Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist

Abstract

The interleukin-1 receptor antagonist (IL-1Ra) is an endogenous protein that can prevent the binding of IL-1 to its cell-surface receptors. Among a number of techniques for gene transfer in vivo, the direct injection of naked DNA into muscle is simple, inexpensive and safe. In this study, we evaluated the potential of intramuscular gene therapy with plasmid DNA containing the cDNA for IL-1Ra in the prevention of murine collagen-induced arthritis (CIA). DBA/1 mice were immunized with bovine type II collagen. At 4 weeks after the initial immunization, expression plasmid for IL-1Ra was injected into four selected sites in the thigh and calf muscles of DBA/1 mice. Control mice received the same plasmid, but lacking the IL-1Ra coding sequence. Macroscopic analysis of paws for redness, swelling and deformities showed that the onset of moderate to severe CIA in the paws of mice injected with IL-1Ra DNA was significantly prevented (P<0.05). In addition, both the synovitis and the cartilage erosion in knee joints were dramatically reduced in mice treated with IL-1Ra DNA (P<0.05). The expression of IL-1β was significantly decreased in the ankle joints of mice treated with IL-1Ra (P<0.01). Interestingly, the levels of IL-1Ra in sera and joints after intramuscular injection of IL-1Ra DNA were significantly lower than when protein had been used in previous reports, suggesting that the therapeutic effect may be achieved by an alternative mechanism(s) rather than by systemic elevation of IL-1Ra. These observations provide the first evidence that direct intramuscular injection of expression plasmid for IL-1Ra may effectively suppress the inflammatory pathology in arthritis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Kaklamanis PM . Experimental animal models resembling rheumatoid arthritis. Clin Rheumatol 1992; 11: 41–47.

    Article  CAS  Google Scholar 

  2. Arend WP, Dayer JM . Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151–160.

    Article  CAS  Google Scholar 

  3. Arner EC, Pratta MA . Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis, and prostaglandin E2 release from cartilage in organ culture. Arthritis Rheum 1989; 32: 288–297.

    Article  CAS  Google Scholar 

  4. Miyasaka N et al. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction. Arthritis Rheum 1988; 31: 480–486.

    Article  CAS  Google Scholar 

  5. van de Loo FA, Arntz OJ, Otterness IG, van den Berg WB . Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J Rheumatol 1992; 19: 348–356.

    CAS  PubMed  Google Scholar 

  6. Eisenberg SP et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341–346.

    Article  CAS  Google Scholar 

  7. Smith RJ, Chin JE, Sam LM, Justen JM . Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991; 34: 78–83.

    Article  CAS  Google Scholar 

  8. Hung GL et al. Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Therapy 1994; 1: 64–69.

    CAS  Google Scholar 

  9. Otani K et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 1996; 156: 3558–3562.

    CAS  Google Scholar 

  10. Dayer JM . The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002; 69: 123–132.

    Article  Google Scholar 

  11. Campion GV et al. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996; 39: 1092–1101.

    Article  CAS  Google Scholar 

  12. Bresnihan B et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–2204.

    Article  CAS  Google Scholar 

  13. Jiang Y et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001–1009.

    Article  CAS  Google Scholar 

  14. Wooley PH et al. The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 1993; 36: 1305–1314.

    Article  CAS  Google Scholar 

  15. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB . Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti- IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996; 39: 797–809.

    Article  CAS  Google Scholar 

  16. Granowitz EV et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4: 353–360.

    Article  CAS  Google Scholar 

  17. Bendele A et al. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498–506.

    Article  CAS  Google Scholar 

  18. Ghivizzani SC et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998; 95: 4613–4618.

    Article  CAS  Google Scholar 

  19. Bakker AC et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997; 40: 893–900.

    Article  CAS  Google Scholar 

  20. Pan RY et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 2000; 43: 289–297.

    Article  CAS  Google Scholar 

  21. Nishikawa M, Huang L . Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861–870.

    Article  CAS  Google Scholar 

  22. Lee Y et al. Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochem Biophys Res Commun 2000; 272: 230–235.

    Article  CAS  Google Scholar 

  23. Lim BK et al. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 2002; 105: 1278–1281.

    Article  CAS  Google Scholar 

  24. Stuart JM, Townes AS, Kang AH . Collagen autoimmune arthritis. Annu Rev Immunol 1984; 2: 199–218.

    Article  CAS  Google Scholar 

  25. Holmdahl R et al. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev 1990; 118: 193–232.

    Article  CAS  Google Scholar 

  26. Piguet PF et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510–514.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Geiger T et al. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 1993; 11: 515–522.

    CAS  PubMed  Google Scholar 

  28. Dinarello CA . Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–1652.

    CAS  Google Scholar 

  29. Hom JT, Bendele AM, Carlson DG . In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol 1988; 141: 834–841.

    CAS  PubMed  Google Scholar 

  30. Nouri AM, Panayi GS, Goodman SM . Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984; 55: 295–302.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. MacNaul KL et al. Analysis of IL-1 and TNF-alpha gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. J Immunol 1990; 145: 4154–4166.

    CAS  Google Scholar 

  32. Marucha PT, Zeff RA, Kreutzer DL . Cytokine-induced IL-1 beta gene expression in the human polymorphonuclear leukocyte: transcriptional and post-transcriptional regulation by tumor necrosis factor and IL-1. J Immunol 1991; 147: 2603–2608.

    CAS  PubMed  Google Scholar 

  33. Bethea JR et al. Interleukin-1 beta induction of tumor necrosis factor-alpha gene expression in human astroglioma cells. J Neuroimmunol 1992; 36: 179–191.

    Article  CAS  Google Scholar 

  34. Song XY et al. Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest 1998; 101: 2615–2621.

    Article  CAS  Google Scholar 

  35. Dreja H, Annenkov A, Chernajovsky Y . Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen-induced arthritis. Arthritis Rheum 2000; 43: 1698–1709.

    Article  CAS  Google Scholar 

  36. Ghivizzani SC et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci USA 1998; 4613–4618.

    Article  CAS  Google Scholar 

  37. Kim SH et al. Ex vivo gene delivery of IL-1Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 2002; 6: 591–600.

    Article  CAS  Google Scholar 

  38. Casares S et al. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med 1997; 186: 1481–1486.

    Article  CAS  Google Scholar 

  39. Parker SE et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999; 10: 741–758.

    Article  CAS  Google Scholar 

  40. Lew D et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995; 6: 553–564.

    Article  CAS  Google Scholar 

  41. Kim JM et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002; 46: 793–801.

    Article  CAS  Google Scholar 

  42. Kim SH et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166: 3499–3505.

    Article  CAS  Google Scholar 

  43. Bessis N et al. Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis. J Gene Med 2002; 4: 300–307.

    Article  Google Scholar 

  44. Lubberts E et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999; 163: 4546–4556.

    CAS  Google Scholar 

Download references

Acknowledgements

J-M Kim and J-G Jeong contributed equally to this work. This work was supported by grant from the Korean Ministry of Health and Welfare (Grant No. 02-PJ1-PG11-VN01-SV01-0031).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, JM., Jeong, JG., Ho, SH. et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 10, 1543–1550 (2003). https://doi.org/10.1038/sj.gt.3302042

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302042

Keywords

This article is cited by

Search

Quick links